Work

Abstract LB366: Zidesamtinib has differentiated preclinical brain penetrance and intracranial activity compared to other ROS1 inhibitors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-lb366

Authors: Anupong Tangpeerachaikul, Joshua C. Horan, Henry E. Pelish

Institution: Nuvalent, Inc. (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154734871

Cites:

Cited by:

Related to: